RxDoctor Payments Data

Abdul Moiz Hafiz, MD

Interventional Cardiology · Springfield, ILNPI 1225397219

Payments from drug & device makers

$23,376in general payments, 2019–2025

Across 90 payments — averaging $259.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$9K
  • Medtronic$5K
  • Edwards Lifesciences$3K
  • Abbott$3K
  • Shockwave Medical, Inc$2K
  • Philips North America LLC$1K
  • plus $375 from 4 others
$645in research payments, 2019–2025

Across 4 payments — averaging $161.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$645

What the payments were for

  • Travel & lodging$10,85173%
  • Food & beverage$4,01527%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,376 in reported general payments places this provider in the 70th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$90,783
Medicare patients
272
Services billed
630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan96$122,716
EliquisApixaban71$96,777
JardianceEmpagliflozin29$34,748
XareltoRivaroxaban12$7,768
Ranolazine ErRanolazine17$1,932
Atorvastatin Calcium186$1,860
Metoprolol Succinate129$1,338
Ezetimibe44$731
Rosuvastatin Calcium49$583
Isosorbide Mononitrate ErIsosorbide Mononitrate39$547
Carvedilol90$527
Amlodipine Besylate87$434
ClopidogrelClopidogrel Bisulfate55$434
Valsartan16$376
Furosemide90$282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$111$7,76812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →